Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yinao Jieyu Granules vs Fluoxetine for Kidney-Deficiency Liver-Stagnation Depression
CTR20211110Phase 2Completed
- Sponsor
- Zhongjing Wanxi Pharmaceutical
- Start
- May 2021
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of Kaixin Changyu Granule in major depressive disorder (MDD), sponsored by Zhongjing Wanxi Pharmaceutical. Started May 2021; status: completed.
02
Drugs
Kaixin Changyu Granule
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on CTR20211110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211110.